| ID | 1102 |
| Name of the vaccine | Shanchol |
| Microbe | Bacteria |
| Disease name | Cholera |
| Name of bacteria | Vibrio cholerae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | Over 1 year |
| Description of the vaccine | Vibrio cholerae vaccine consisting of killed whole-cell O1 and O139 serogroups without CTB. |
| Name of the manufacturer | Shantha Biotechnics Limited |
| Name of the manufacturing country | India |
| Year of manufacture | 2009 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | 67% protection against V. cholerae O1 cholera. |
| Vaccine formulation | Suspension |
| Dosage | 1.5 mL. The primary immunization schedule includes two doses, at an interval of two weeks. |
| Mechanism of action | Acts locally in the gastrointestinal tract to induce an IgA antibody response. |
| Route of administration | Oral |
| Indications | Data for the safety and efficacy of the vaccine in infants is not available. |
| Export | NA |
| Approval | WHO pre-qualified(2011) |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Acute Gastroenteritis, diarrhoea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth. |
| Post vaccination | Medical supervision for at least 30 minutes after vaccination. |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.who.int/immunization_standards/vaccine_quality/pq_250_cholera_1dose_shantha_insert.pdf?ua=1, |
| Other name | NA |
| Additional Links | NA
|